Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.

Eur Heart J · 2023 · PMC9805406 · PMID 36254693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

There was a strong trend toward more pronounced clinical benefit among patients with a greater increase in haematocrit (above the median) with the win ratios (95% CI) at Days 15 and 30 in the placebo group: 1.36 (0.96, 1.92) and 1.36 (0.96, 1.92), respectively, and in the empagliflozin group 1.33 (0.93, 1.90) and 1.42 (1.00, 2.01) ( Figure 5B and C ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.